home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

58.51 -0.56 (-0.95%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗

February 21, 2023

Via Benzinga

3 Prime Healthcare Takeover Targets ↗

February 14, 2023

These three companies are attractive targets for their potential.

Via The Motley Fool

Moderna Stock Getting Closer To Key Technical Benchmark ↗

February 10, 2023

On Friday, biotech Moderna stock received an upgrade to its Relative Strength (RS) Rating, to 72 from 69 a day earlier.

Via Investor's Business Daily

BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst ↗

January 30, 2023

Via Benzinga

What 5 Analyst Ratings Have To Say About Biomarin Pharmaceutical ↗

January 30, 2023

Via Benzinga

6 Analysts Have This to Say About Biomarin Pharmaceutical ↗

January 11, 2023

Via Benzinga

2 Top Biotech Stocks Defying the Bear Market ↗

January 10, 2023

Some stocks are hitting new highs.

Via The Motley Fool

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results ↗

February 03, 2023

Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗

January 30, 2023

Via Benzinga

3 Drug Stocks With Promising Pipelines for 2023 ↗

January 23, 2023

These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors.

Via InvestorPlace

Expert Ratings for Biomarin Pharmaceutical ↗

November 29, 2022

Via Benzinga

Expert Ratings for Biomarin Pharmaceutical ↗

October 31, 2022

Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:

Via Benzinga

Why BioMarin Pharmaceuticals Fell 6.9% on Thursday ↗

October 27, 2022

Investors were expecting better top-line numbers from the company's earnings report.

Via The Motley Fool

Cramer Is Holding This Biotech Stock ↗

January 12, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutical Inc (NASDAQ: BMRN).

Via Benzinga

Vertex Pharmaceuticals Stock Sees Rising Relative Strength ↗

January 11, 2023

A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

BioMarin's Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target ↗

January 11, 2023

Via Benzinga

Top Picks For 2023: Catalyst Pharmaceuticals ↗

January 02, 2023

Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top...

Via Talk Markets

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 01, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

December 01, 2022

Good morning! We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about!

Via InvestorPlace

Expert Ratings for Biomarin Pharmaceutical ↗

October 13, 2022

Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter:

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 29, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate ↗

November 23, 2022

Via Benzinga

The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath ↗

November 23, 2022

And shares of its developer are on a warpath this week.

Via Investor's Business Daily

Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today ↗

November 23, 2022

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are trading higher by 6.97% to $97.54 Wednesday morning after the company announced advancements in the FDA review of ROCTAVIAN for adults with severe...

Via Benzinga

$1.4 Million Bet On This Real Estate Stock? 3 Stocks Insiders Are Buying ↗

November 03, 2022

Although US stocks closed lower on Wednesday, there were a few notable insider trades.

Via Benzinga

10 Analysts Have This to Say About Biomarin Pharmaceutical ↗

October 31, 2022

Over the past 3 months, 10 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ:BMRN) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗

October 31, 2022

Upgrades

Via Benzinga

Mastercard To $428? Plus This Analyst Slashes PT On Intel ↗

October 31, 2022

Barclays cut the price target on Mastercard Incorporated (NYSE: MA) from $430 to $428. Barclays analyst Ramsey El-Assal maintained an Overweight rating on the stock. Mastercard shares fell 0.6% to...

Via Benzinga

Biomarin Pharmaceutical: Q3 Earnings Insights ↗

October 26, 2022

Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:03 PM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: Biomarin Pharmaceutical Q3 Earnings ↗

October 26, 2022

Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com